Richard S. Foemmel
Plus aucun poste en cours
Profil
Richard S.
Foemmel was the founder of Cytologix Corp.
founded in 1979, where he held the position of President & Chief Executive Officer from 2009 to 2012.
He is also the founder of DecImmune Therapeutics, Inc. Dr. Foemmel's former job was as Vice President at DIANON Systems, Inc. Dr. Foemmel holds an MBA degree from New York University and a doctorate degree from the University of Michigan.
Anciens postes connus de Richard S. Foemmel
| Sociétés | Poste | Fin |
|---|---|---|
DIANON Systems, Inc.
 DIANON Systems, Inc. Medical/Nursing ServicesHealth Services Dianon Systems, Inc. provides anatomic pathology, genetic, and clinical chemistry testing services. The firm offers services in uropathology, dermatopathology, gastrointestinal pathology, hematopathology, and breast pathology. The company was founded in 1983 and is headquartered in Stratford, CT. | Corporate Officer/Principal | - |
DecImmune Therapeutics, Inc.
 DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Fondateur | - |
Cytologix Corp.
 Cytologix Corp. Miscellaneous Commercial ServicesCommercial Services The number of people suffering from cancer is constantly growing. A key factor in ensuring patients the best treatment is to make an accurate and full diagnosis and choose the right form of treatment at an early stage. At Dako it builds its business to constantly improve cancer diagnostics. The pathology lab is where all cancer related diagnoses are being prepared and where they have its main focus. By focusing on the entire workflow of the pathology labs worldwide they believe that they can contribute in improving quality, safety and cost efficiency for the benefit of the doctors, the lab and especially the patients waiting for results. The strategic focus of Dako is centered on workflow in the pathology laboratory with the aim of: 1. Reducing time from biopsy to diagnosis 2. Improving quality and reliability of the diagnosis 3. Reducing laboratory costs. The company goal is to help its customers help their patients the most human way possible. They work closely with doctors and experts in the field of cancer diagnostics to ensure they stay at the forefront of their needs and the market development. Partnering is a way for to get access to relevant technologies outside its own core competencies. They aim to be an attractive partner and employer and have a highly trained and skilled international staff to develop, manufacture and market its products all over the world. Its organization is spread world wide. They stay in close relations and support openness and dialogue as an important element in the way they work. Dako is a global business with headquarters in Denmark. It was founded by the Danish medical doctor Niels Harboe in 1966 and has more than 40 years' experience in the development and production of reagents and antibodies. | Fondateur | - |
Formation de Richard S. Foemmel
| University of Michigan | Doctorate Degree |
| New York University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Cytologix Corp.
Cytologix Corp. Miscellaneous Commercial ServicesCommercial Services The number of people suffering from cancer is constantly growing. A key factor in ensuring patients the best treatment is to make an accurate and full diagnosis and choose the right form of treatment at an early stage. At Dako it builds its business to constantly improve cancer diagnostics. The pathology lab is where all cancer related diagnoses are being prepared and where they have its main focus. By focusing on the entire workflow of the pathology labs worldwide they believe that they can contribute in improving quality, safety and cost efficiency for the benefit of the doctors, the lab and especially the patients waiting for results. The strategic focus of Dako is centered on workflow in the pathology laboratory with the aim of: 1. Reducing time from biopsy to diagnosis 2. Improving quality and reliability of the diagnosis 3. Reducing laboratory costs. The company goal is to help its customers help their patients the most human way possible. They work closely with doctors and experts in the field of cancer diagnostics to ensure they stay at the forefront of their needs and the market development. Partnering is a way for to get access to relevant technologies outside its own core competencies. They aim to be an attractive partner and employer and have a highly trained and skilled international staff to develop, manufacture and market its products all over the world. Its organization is spread world wide. They stay in close relations and support openness and dialogue as an important element in the way they work. Dako is a global business with headquarters in Denmark. It was founded by the Danish medical doctor Niels Harboe in 1966 and has more than 40 years' experience in the development and production of reagents and antibodies. | Commercial Services |
DIANON Systems, Inc.
DIANON Systems, Inc. Medical/Nursing ServicesHealth Services Dianon Systems, Inc. provides anatomic pathology, genetic, and clinical chemistry testing services. The firm offers services in uropathology, dermatopathology, gastrointestinal pathology, hematopathology, and breast pathology. The company was founded in 1983 and is headquartered in Stratford, CT. | Health Services |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Health Technology |
